| Autor: |
Sozaeva LS; Endocrinology Research centre., Makazan NV; Endocrinology research centre., Nikankina LV; Endocrinology Research centre., Malysheva NM; Endocrinology Research centre., Kuvaldina EV; The Russian National Research Medical University named after N.I. Pirogov., Kareva MA; Endocrinology research centre., Orlova EM; Endocrinology research centre., Peterkova VA; Endocrinology Research centre. |
| Jazyk: |
ruština |
| Zdroj: |
Problemy endokrinologii [Probl Endokrinol (Mosk)] 2020 Jun 10; Vol. 65 (6), pp. 466-473. Date of Electronic Publication: 2020 Jun 10. |
| DOI: |
10.14341/probl12106 |
| Abstrakt: |
Primary adrenal insufficiency is manifested by a deficiency of adrenal cortex hormones and can lead to a life-threatening condition. Early diagnosis is key to patient survival. Auto-antibodies to one of the adrenal steroidogenesis enzymes, 21-hydroxylase, are an immunological marker of autoimmune adrenal insufficiency. On the one hand, the study of antibodies to 21-hydroxylase is a method that helps establish the etiology of the disease – the autoimmune genesis of adrenal gland damage. On the other hand, the determination of autoantibodies to 21-hydroxylase is the only prognostic factor of the risk of adrenal insufficiency, which makes it possible to prevent the development of acute adrenal crisis. The article provides a brief literature review on autoantibodies to 21-hydroxylase and the pathogenesis of autoimmune adrenal insufficiency, and a series of clinical cases that illustrates the significant role of autoantibodies to 21-hydroxylase in diagnosis of adrenal insufficiency. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
